ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
 PMID: 30476106       2019       The Journal of antimicrobial chemotherapy
Abstract: We studied the prevalence of doravirine resistance-associated mutations previously identified in vitro: V106A/M, V108I, Y188L, V190S, H221Y, F227C/L/V, M230I/L, L234I, P236L, Y318F and K103N/Y181C.


  Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods.
 PMID: 30741163       2019       Antiviral therapy
Abstract: Inclusion of all nine of South Africa's provinces in the 2012 survey enabled calculation of a national TDR point prevalence estimate: TDR to the NNRTI drug class was 5.4% (95% CI 3.7, 7.8%), with K103N and V106M being the most frequently detected mutations.


  Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
 PMID: 30769200       2019       International journal of antimicrobial agents
Abstract: High-level DOR resistance was defined as detection of any of Y188L, M230L, G190E, V106A/M+F227L, and V106A/M+L234I.
Abstract: Intermediate DOR resistance was defined as detection of any of V106A/M, Y188C/H, V108I, and K103N+P225H.


  HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases.
 PMID: 30798679       2019       Journal of the International Association of Providers of AIDS Care
Conclusion: The genotype performed at this time showed the following protease inhibitor gene mutations: I13I/V, E35D, D60E, L63P, I64V, and V77I and RT mutation V106I/V/M conferring resistance to efavirenz and nevirapine.


  Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens.
 PMID: 30863788       2019       Open forum infectious diseases
Introduction: Studies of drug resistance mutations (DRMs) in plasma virus ribonucleic acid (RNA) by Sanger consensus sequencing frequently identify mutations a
Method: Nucleoside reverse-transcriptase inhibitor DRMs included M41I/L, D67N/E, K70R, M184V, T215Y/F/C/S, K219Q/E; NNRTI DRM included K103N, Y181C, G190A/S/R, L100I, K101E, V106I/M, Y188H/C/L, M230I/L.


  Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
 PMID: 30989237       2019       The Journal of antimicrobial chemotherapy
Result: Other mutations observed with a frequency of 2.0% were as follows: for NRTIs, D67N (n = 1), K70R (n = 1) and K219E (n = 1); and for NNRTIs, V106AM (n = 1) and G190A (n = 1) (Figure 1).


  Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.
 PMID: 31778107       2019       Current HIV research
Discussion: EFV and NVP, which are both NNRTIs, had the highest drug resistance rate in this study which was mainly caused by K103N, V179D, V106M and E138G/Q mutations.


  HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017.
 PMID: 31651864       2019       Medicine
Result: K103N/KN (155/372, 41.67%), V106M/MA/MV (107/372, 28.76%), G190A/AG/S (103/372, 27.69%), and Y181C/CY (89/372, 23.92%) were the major NNRTI-related mutations.
Discussion: We observed that K103N/KN, V106M/MA/MV, G190A/AG/S, and Y188L/C are the major NNRTI-related mutations in China and other countries, which may be the result of the wide-spread use of NNRTIs.


  Molecular Genetics and the Incidence of Transmitted Drug Resistance Among Pre-Treatment HIV-1 Infected Patients in the Eastern Cape, South Africa.
 PMID: 31584370       2019       Current HIV research
Abstract: K103N/S, V106M and M184V were the most common mutations identified among the viral sequences.


  Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
 PMID: 31430369       2019       The Journal of antimicrobial chemotherapy
Method: Primary NNRTI-R substitutions were L100I, K101E/P, K103N/S, V106M/A, V108I, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188C/H/L, G190A/E/Q/S, H221Y, P225H, F227C and M230L/I in RT.



Browser Board

 Co-occurred Entities




   Filtrator